Focus Partners Wealth’s NovoCure NVCR Stock Holding History

Focus Partners Wealth’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.11M	Sell	73,177 -12,606	-15%	-$191K	﹤0.01%	1615
2026 Q1	$968K	Sell	85,783 -2,398	-3%	-$30K	﹤0.01%	1640
2025 Q4	$1.14M	Buy	+88,181	New	+$1.13M	﹤0.01%	1580
2025 Q3	–	Sell	-93,832	Closed	-$1.67M	–	2280
2025 Q2	$1.67M	Buy	93,832 +1,495	+2%	+$26.1K	﹤0.01%	959
2025 Q1	$1.65M	Sell	92,337 -535	-0.6%	-$12.2K	﹤0.01%	907
2024 Q4	$2.77M	Sell	92,872 -2,624	-3%	-$55.5K	0.01%	766
2024 Q3	$1.49M	Buy	95,496 +582	+0.6%	+$10.6K	﹤0.01%	844
2024 Q2	$1.63M	Buy	94,914 +1,629	+2%	+$28.6K	0.01%	695
2024 Q1	$1.46M	Buy	93,285 +39,320	+73%	+$578K	0.01%	535
2023 Q4	$806K	Buy	+53,965	New	+$722K	0.01%	488

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Focus Partners Wealth's NVCR Position: Q2 2026 in Review

Focus Partners Wealth reduced its NovoCure (NVCR) stake by 15% in Q2 2026, selling an estimated $191K and leaving 73,177 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1615.

Focus Partners Wealth first reported a position in NVCR in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.77M in Q4 2024. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Focus Partners Wealth held 73,177 shares of NovoCure worth $1.11M as of Q2 2026.
Focus Partners Wealth sold 12,606 NovoCure shares in Q2 2026, an estimated $191K.
NovoCure made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #1615 holding.
Focus Partners Wealth first reported a position in NovoCure in Q4 2023 and has held it in 10 quarters since.
Focus Partners Wealth's NovoCure position peaked at $2.77M in Q4 2024.
216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.